Endurance RP (0575) AI Stock Analysis

• Market Cap: HK$201.35M
• Dividend Yield: N/A
• Average Volume (3M): 43.07K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.59
• Revenue Growth: 334.18%
• EPS Growth: 73.87%
• Country: HK
• Employees: 18
• Sector: Healthcare
• Sector Strength: 45
• Industry: Asset Management
• EPS (TTM): -0.07
• Shares Outstanding: 291,815,800
• 10 Day Avg. Volume: 26,365
• 30 Day Avg. Volume: 43,074
• PEG Ratio: 0.03
• Price to Book (P/B): -1.82
• Price to Sales (P/S): 14.92
• P/FCF Ratio: -2.59
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 40 Underperform
• Price Target: HK$0.50 ▼(-25.37% Downside)

Endurance RP's overall stock score is significantly impacted by its poor financial performance, characterized by persistent losses and negative equity. Technical analysis indicates bearish momentum, while valuation metrics highlight ongoing profitability challenges. The lack of earnings call and corporate events data limits additional insights.

Endurance RP Business Overview & Revenue Model

Company Description

Endurance RP (0575) is a leading provider of high-performance endurance sports equipment and apparel, specializing in products that enhance athletic performance and comfort for runners, cyclists, and triathletes. The company operates within the sports and fitness sector, focusing on innovative designs and sustainable materials to meet the needs of both amateur and professional athletes. Core offerings include footwear, apparel, and accessories tailored for endurance sports, along with personalized training programs and coaching services.

How the Company Makes Money

Endurance RP generates revenue through multiple streams, primarily from direct sales of its high-performance sports equipment and apparel through both online and physical retail channels. The company also offers subscription-based personalized training programs, which provide additional recurring revenue. Key partnerships with fitness influencers and sponsorship deals with endurance events and competitions enhance brand visibility and drive sales. Moreover, collaboration with health and wellness organizations allows for the development of exclusive products, further contributing to earnings.

Endurance RP Financial Statement Overview

Summary

Endurance RP faces significant financial challenges across all verticals. Despite strong revenue growth, the company remains unprofitable with negative margins and equity, indicating potential insolvency risks. Cash flow shows slight improvement, but operational cash generation remains a critical issue.

Income Statement

The income statement reveals significant challenges, with persistent negative margins across gross profit, net income, and EBIT. Despite a notable revenue growth rate of 185.32% in the latest year, the company remains unprofitable, with a net profit margin of -6.23%. The EBITDA margin is positive at 25.05%, indicating some operational efficiency, but overall profitability remains elusive.

Balance Sheet

The balance sheet shows a concerning financial structure with negative stockholders' equity, indicating potential insolvency risks. The debt-to-equity ratio is negative, reflecting the negative equity, and the return on equity is positive due to negative net income and equity, which is not a favorable sign. The equity ratio is not calculable due to negative equity, highlighting financial instability.

Cash Flow

Cash flow analysis shows a slight improvement in free cash flow growth at 9.42%, but operating cash flow remains negative. The free cash flow to net income ratio is slightly above 1, indicating that free cash flow covers net income, but the negative operating cash flow to net income ratio suggests ongoing operational cash challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	913.00K	719.00K	382.00K	114.00K	3.25M	1.67M
Gross Profit	118.00K	-219.00K	-2.34M	-1.11M	850.00K	-788.00K
EBITDA	18.49M	18.01M	-7.72M	-9.56M	10.38M	-4.48M
Net Income	-4.08M	-4.48M	-25.05M	-36.43M	-12.60M	-24.40M
Balance Sheet
Total Assets	734.00K	610.00K	2.79M	26.32M	62.23M	80.31M
Cash, Cash Equivalents and Short-Term Investments	147.00K	121.00K	2.42M	1.41M	11.13M	5.21M
Total Debt	1.77M	3.34M	1.20M	13.73M	14.01M	14.01M
Total Liabilities	4.90M	6.51M	4.35M	23.72M	23.46M	30.00M
Stockholders Equity	-4.17M	-5.90M	-1.55M	2.60M	38.77M	50.30M
Cash Flow
Free Cash Flow	-3.75M	-4.13M	-3.59M	533.00K	-1.75M	-5.73M
Operating Cash Flow	-3.73M	-4.13M	-3.59M	545.00K	-1.70M	-5.72M
Investing Cash Flow	-233.00K	-3.00K	-1.00K	-7.00K	123.00K	1.83M
Financing Cash Flow	3.84M	2.14M	5.58M	-795.00K	-782.00K	6.54M

Endurance RP Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.67
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0575, the sentiment is Negative. The current price of 0.67 is below the 20-day moving average (MA) of 0.68, below the 50-day MA of 0.73, and below the 200-day MA of 0.73, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 46.27 is Neutral, neither overbought nor oversold. The STOCH value of 84.85 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0575.

Endurance RP Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
0174	41 Neutral	HK$137.92M	-0.76	―	―	-22.77%	40.53%
8657	41 Neutral	HK$207.65M	-5.34	-70.47%	―	-3.35%	42.21%
0575	40 Underperform	HK$201.35M	―	―	―	334.18%	73.87%
1226	39 Underperform	HK$325.95M	-59.40	-3.51%	―	―	85.46%

Endurance RP Corporate Events

Endurance RP Reports Reduced Loss and Progress in Key Markets

Endurance RP has reported a reduced loss of approximately US$2.22 million for the first half of 2025, primarily due to operating and R&D expenses. The company is making progress with its product Senstend™ in China, aiming for marketing approval by the end of 2025 and a commercial launch in early 2026. Additionally, Endurance RP is evaluating proposals for phase 3 clinical studies of Fortacin™ in the US and is in discussions for out-licensing opportunities. The company continues to supply Fortacin™ to European markets and is negotiating manufacturing terms in South-East Asia. Endurance RP is also advancing its Deep Longevity division, focusing on AI-driven aging clocks and expanding its business development strategies.

Regent Pacific Schedules Board Meeting for Interim Results

Regent Pacific Group Limited, a company listed on the Hong Kong Stock Exchange, has announced an upcoming board meeting scheduled for August 27, 2025. The meeting will focus on approving the interim results for the first half of 2025 and considering the payment of an interim dividend, which could impact the company’s financial outlook and shareholder returns.